HopeStage
Back to all studies
Completed2015-003503-39

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

Interventional studyAges 13–20Multiple countriesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 13 years to 20 years.

Listed locations
Vienna and 13 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 30, 2016
Recruitment status
Completed
Enrollment listed in the registry
145
Sponsor
Rene Kahn
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom, Switzerland, Austria, ...
Age range
From 13 Years to 20 Years
Official registry ID
2015-003503-39
Official title
Show the full official title

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vienna, Austria · Tübingen, Germany · Petah Tikva, Israel

9 more locations
  • Ramat Gan, Israel
  • Rome, Italy
  • Utrecht, Netherlands
  • Bergen, Norway
  • Barcelona, Spain
  • Madrid, Spain
  • Santander, Spain
  • Zurich, Switzerland
  • Edinburgh, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Rene Kahn.

Did this study involve medication?

Yes. The study involved medication, including Omega-3 fatty acids.

Who was this study for?

Listed age limits: 13 years to 20 years.

Want to explore more studies?

Explore studies